The topic of women's right to abortion in the United States sparked public opinion this past weekend, as the divisive U.S. Supreme Court formally announced on Friday that it had overturned the 1973 decision in Roe v. Wade.

The historic decision of the U.S. Supreme Court on Friday could make abortion illegal in most of the United States and further tear American society apart, Bloomberg reported.

The surge in demand for contraceptive has forced two major pharmacy chains, CVS and Rite Aid, to impose restrictions on purchases, temporarily limiting the purchase of three tablets per customer, the report said.

And after the case of Law v. Wade was overturned,According to the financial news website Benzinga, in the US stock market$Evofem Biosciences (EVFM.US) $、$Agile Therapeutics (AGRX.US) $And$Dare Bioscience (DARE.US) $Shares of small-cap health care stocks performed well on Monday.

• Evofem Biosciences, a new American contraceptive producer

Evofem surged 187 per cent to $1.07 on Monday, with a latest market capitalization of $14 million, continuing the rally that followed Friday's overthrow of the abortion bill by the US Supreme Court, up about 240 per cent in two sessions.

Its contraceptive gel Phexxi is the first non-hormonal contraceptive approved by FDA in nearly 30 years. Compared with traditional contraceptive methods, this gel does not need regular oral administration or forced regulation of female hormones to achieve contraception, it mainly through the regulation of pH to achieve the purpose of contraception.

Four Wall Street analysts are tracking the stock, with a consensus rating of "moderate buy" and an average target price of $2.63, with 145 per cent room to rise from current levels, according to Tipranks.

• Female contraceptive & Johnson specialist Pharmaceutical Company Agile Therapeutics

Agile closed up more than 10 per cent at $1.27 on Monday, with its latest market capitalisation of $6 million, up nearly 6 per cent in the past two trading sessions. The company's approved product, prescription contraceptive patch Twirla, contains ethinylestradiol and levonorgestrel, the two most common hormones in short-acting oral contraceptive. The drug has a contraceptive effect by applying a tablet to the abdomen, buttocks or upper torso every week.

In the past three months, only two Wall Street analysts have covered the stock, with an average target price of $60, according to Tipranks.

• Healthcare company Dare Bioscience

Dare Biosciences closed up nearly 7 per cent at $1.38 on Monday, with its latest market capitalisation of $117 million, up more than 5 per cent in the past two sessions. The company had previously reached a strategic partnership with Bayer to develop vaginal ring Ovaprene, a research hormone-free monthly vaginal contraceptive product.

All four analysts tracking the stock now have a "buy" rating, with an average target price of $4.75, with 244 per cent room to rise from the current level, according to Tipranks.

What needs to be reminded is that in the US stock market, small market capitalization pharmaceutical companies are often prone to capital speculation, and the market fluctuates greatly. I hope you can keep your eyes open, make prudent decisions, and wish you smooth investment.